{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:57:00Z","timestamp":1777679820595,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:p>Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy &amp; Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy\/nursing in-services. A comprehensive target drug utilization evaluation\/medication use evaluation (DUE\/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The March 2015 monograph topics are paritaprevir, ritonavir, ombitasvir, and dasabuvir; meningococcal B bivalent recombinant vaccine; alemtuzumab; ceftolozane\/tazobactam; and peramivir solution. The Safety MUE is on peramivir solution.<\/jats:p>","DOI":"10.1310\/hpj5003-224","type":"journal-article","created":{"date-parts":[[2015,3,18]],"date-time":"2015-03-18T21:37:16Z","timestamp":1426714636000},"page":"224-234","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Ledipasvir\/Sofosbuvir"],"prefix":"10.1177","volume":"50","author":[{"given":"Dennis J.","family":"Cada","sequence":"first","affiliation":[{"name":"The Formulary;, College of Pharmacy, Washington State University Spokane, PO Box 1495, Spokane, Washington 99210-1495"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danial E.","family":"Baker","sequence":"additional","affiliation":[{"name":"Drug Information Center, and College of Pharmacy, Washington State University Spokane, PO Box 1495, Spokane, Washington 99210-1495"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross Jason","family":"Bindler","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Washington State University."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,3,1]]},"reference":[{"key":"bibr1-hpj5003-224","volume-title":"Harvoni (ledipasvir\/sofosbuvir) [prescribing information].","year":"2014"},{"key":"bibr2-hpj5003-224","unstructured":"CoxE. FDA approval letter:\n                      Harvoni\n                      (ledipasvir\/sofosbuvir NSA 205834). US Food and Drug Administration Web site. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2014\/205834Orig1s000ltr.pdf. Published October 10, 2014. Accessed October 24, 2014."},{"key":"bibr3-hpj5003-224","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"bibr4-hpj5003-224","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"bibr5-hpj5003-224","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"bibr6-hpj5003-224","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62121-2"},{"key":"bibr7-hpj5003-224","unstructured":"Ledipasvir and sofosbuvir. ClinicalTrials.gov Web site. http:\/\/www.clinicaltrials.gov\/ct2\/results?term=ledipasvir+AND+sofosbuvir. Accessed October 24, 2014."},{"key":"bibr8-hpj5003-224","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27053"},{"key":"bibr9-hpj5003-224","volume":"59","author":"Thompson A.","year":"2013","journal-title":"J Hepatol."},{"key":"bibr10-hpj5003-224","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(13)60015-X"},{"key":"bibr11-hpj5003-224","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1302973"},{"key":"bibr12-hpj5003-224","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis393"},{"key":"bibr13-hpj5003-224","volume-title":"Victrelis (boceprevir) [prescribing information].","year":"2014"},{"key":"bibr14-hpj5003-224","volume-title":"Olysio (simeprevir) [prescribing information].","year":"2014"},{"key":"bibr15-hpj5003-224","volume-title":"Sovaldi (sofosbuvir) [prescribing information].","year":"2013"},{"key":"bibr16-hpj5003-224","doi-asserted-by":"publisher","DOI":"10.1021\/jm401499g"},{"key":"bibr17-hpj5003-224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.029"},{"key":"bibr18-hpj5003-224","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02193-12"},{"key":"bibr19-hpj5003-224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2012.12.020"},{"key":"bibr20-hpj5003-224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.018"},{"issue":"4","key":"bibr21-hpj5003-224","first-page":"1066A","volume":"56","author":"Hebner C.","year":"2012","journal-title":"Hepatology."},{"issue":"4","key":"bibr22-hpj5003-224","first-page":"711A","volume":"56","author":"Han B.","year":"2012","journal-title":"Hepatology."},{"issue":"4","key":"bibr23-hpj5003-224","first-page":"551A","volume":"56","author":"Svarovskaia E.S.","year":"2012","journal-title":"Hepatology."},{"key":"bibr24-hpj5003-224","author":"Kirby B.","year":"2014","journal-title":"Population pharmacokinetic analysis of ledipasvir (GS-5885) in healthy and hepatitis C virus infected subjects."},{"key":"bibr25-hpj5003-224","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.346"},{"key":"bibr26-hpj5003-224","author":"German P.","year":"2014","journal-title":"Effect of food and acid reducing agents on the relative bio-availability and pharmacokinetics of ledipasvir and sofosbuvir fixed dose combination tablet."},{"key":"bibr27-hpj5003-224","unstructured":"Guidelines: Recommendations for testing, managing, and treating hepatitis C. American Association for the Study of Liver Disease & Infectious Diseases Society of America. http:\/\/www.hcvguidelines.org\/fullreport.Published August 11, 2014. Accessed September 9, 2014."},{"key":"bibr28-hpj5003-224","unstructured":"Chronic hepatitis C virus (HCV) infection: Treatment considerations from the Department of Veterans Affairs National Hepatitis C Resource Center Program and the Office of Public Health. http:\/\/www.hepatitis.va.gov\/pdf\/2014hcv.pdf. Revised May 13, 2014. Accessed September 9, 2014."},{"key":"bibr29-hpj5003-224","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.11.007"},{"key":"bibr30-hpj5003-224","author":"German P.","year":"2014","journal-title":"Evaluation of the effect of ledipasvir on the QT\/QTc interval in healthy subjects."},{"key":"bibr31-hpj5003-224","author":"German P.","year":"2014","journal-title":"Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals."}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1310\/hpj5003-224","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1310\/hpj5003-224","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1310\/hpj5003-224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:33:38Z","timestamp":1777451618000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1310\/hpj5003-224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1310\/hpj5003-224"],"URL":"https:\/\/doi.org\/10.1310\/hpj5003-224","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}